Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MEDCL.PA
- Price
- 12.87
- Stock movement down
- -0.75 (-5.51%)
- Company name
- Medincell SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 374.40M
- Ent value
- 432.71M
- Price/Sales
- 29.04
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -107.13%
- Trailing P/E
- -
- Forward P/E
- 321.75
- PEG
- -
- EPS growth
- -4.66%
- 1 year return
- 38.24%
- 3 year return
- 32.76%
- 5 year return
- 7.70%
- 10 year return
- -
Last updated: 2025-04-10
DIVIDENDS
MEDCL.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 29.04 |
| Price to Book | - |
| EV to Sales | 33.56 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.09M |
| EPS (TTM) | -1.55 |
| FCF per share (TTM) | -1.24 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.89M |
| Gross profit (TTM) | 16.17M |
| Operating income (TTM) | -38.34M |
| Net income (TTM) | -43.30M |
| EPS (TTM) | -1.55 |
| EPS (1y forward) | 0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 125.43% |
| Operating margin (TTM) | -297.37% |
| Profit margin (TTM) | -335.82% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.46M |
| Net receivables | 2.25M |
| Total current assets | 27.26M |
| Goodwill | -1.00K |
| Intangible assets | 2.45M |
| Property, plant and equipment | 10.83M |
| Total assets | 36.95M |
| Accounts payable | 1.85M |
| Short/Current long term debt | 58.96M |
| Total current liabilities | 16.47M |
| Total liabilities | 77.77M |
| Shareholder's equity | -40.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.60M |
| Capital expenditures (TTM) | 1.08M |
| Free cash flow (TTM) | -34.69M |
| Dividends paid (TTM) | 37.16M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -117.19% |
| Return on Invested Capital | 106.07% |
| Cash Return on Invested Capital | 84.97% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 13.34 |
| Daily high | 13.35 |
| Daily low | 12.84 |
| Daily Volume | 54K |
| All-time high | 18.64 |
| 1y analyst estimate | 22.37 |
| Beta | 1.20 |
| EPS (TTM) | -1.55 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Jun 2025 |
Downside potential
Loading...
Downside potential data
| MEDCL.PA | S&P500 | |
| Current price drop from All-time high | -30.95% | -10.49% |
| Highest price drop | -70.46% | -56.47% |
| Date of highest drop | 25 Aug 2022 | 9 Mar 2009 |
| Avg drop from high | -34.48% | -11.07% |
| Avg time to new high | 79 days | 12 days |
| Max time to new high | 862 days | 1805 days |
COMPANY DETAILS
Marketcap
374.40M
Marketcap category
Small-cap
Description
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Employees
134
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
MONTPELLIER, France, March 31, 2025--Regulatory News: Medincell (Paris:MEDCL):
March 31, 2025
In March 2025, the European markets have shown resilience, with the STOXX Europe 600 Index ending higher after two weeks of losses, driven by optimism around potential government spending despite ongo...
March 28, 2025
As European markets navigate a complex landscape marked by hopes of increased government spending and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to snap two weeks...
March 24, 2025
MONTPELLIER, France, March 06, 2025--Regulatory News: Medincell (Paris:MEDCL):
March 6, 2025
As European markets navigate a landscape marked by cautious optimism amid U.S. trade policy developments and geopolitical efforts, investors are increasingly focused on companies with strong growth po...
February 27, 2025
MONTPELLIER, France, February 26, 2025--Regulatory News: Medincell (Paris:MEDCL):
February 26, 2025
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Eur...
February 25, 2025
MONTPELLIER, France, February 19, 2025--Regulatory News: Medincell (Paris:MEDCL):
February 19, 2025
MONTPELLIER, France, February 18, 2025--Regulatory News: Medincell (Paris:MEDCL):
February 18, 2025
MONTPELLIER, France, February 10, 2025--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE
February 10, 2025
Next page